Anti-HIP1R antibody (ab226197)
- Datasheet
- References
- Protocols
Overview
-
Product name
Anti-HIP1R antibody
See all HIP1R primary antibodies -
Description
Rabbit polyclonal to HIP1R -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Sheep, Rabbit, Horse, Cow, Cat, Dog, Pig, Chimpanzee, Rhesus monkey, Gorilla, Orangutan, Giant Panda
-
Immunogen
Synthetic peptide within Human HIP1R aa 300-350. The exact sequence is proprietary.
Database link: O75146 -
Positive control
- WB: HeLa, HEK-293T and Jurkat whole cell lysate (ab7899). IP: HEK-293T whole cell lysate.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8 -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
ab226197 was affinity purified using an epitope specific to HIP1R immobilized on solid support. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab226197 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/2000 - 1/10000. Predicted molecular weight: 70,119 kDa. | |
| IP | Use at 2-10 µg/mg of lysate. |
Target
-
Function
Component of clathrin-coated pits and vesicles, that may link the endocytic machinery to the actin cytoskeleton. Binds 3-phosphoinositides (via ENTH domain). May act through the ENTH domain to promote cell survival by stabilizing receptor tyrosine kinases following ligand-induced endocytosis. -
Tissue specificity
Brain, heart, kidney, pancreas, and liver, but not in lung or placenta. -
Sequence similarities
Belongs to the SLA2 family.
Contains 1 ENTH (epsin N-terminal homology) domain.
Contains 1 I/LWEQ domain. -
Domain
Binds F-actin via the talin-like I/LWEQ domain. -
Cellular localization
Cytoplasm > perinuclear region. Endomembrane system. Cytoplasmic vesicle > clathrin-coated vesicle membrane. Membrane-associated protein, mainly localized at the endocytic compartments and in the perinuclear region. - Information by UniProt
-
Database links
- Entrez Gene: 100613620 Chimpanzee
- Entrez Gene: 100060573 Horse
- Entrez Gene: 9026 Human
- Entrez Gene: 29816 Mouse
- Entrez Gene: 707396 Rhesus monkey
- Omim: 605613 Human
- SwissProt: O75146 Human
- SwissProt: Q9JKY5 Mouse
see all -
Alternative names
- FLJ14000 antibody
- FLJ27022 antibody
- HIP-12 antibody
see all
Images
-
Western blot - Anti-HIP1R antibody (ab226197)All lanes : Anti-HIP1R antibody (ab226197) at 0.1 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate
Lane 3 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Lysates/proteins at 50 µg per lane.
Developed using the ECL technique.
Predicted band size: 70,119 kDa
Exposure time: 10 secondsCell lysates were prepared using NETN lysis buffer.
-
Immunoprecipitation - Anti-HIP1R antibody (ab226197)HIP1R was immunoprecipitated from HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (20% of IP loaded) with ab226197 at 6 µg per reaction. Western blot was performed from the immunoprecipitate using ab226197 at 0.4 µg/ml.
Lane 1: ab226197 IP in HEK-293T whole cell lysate.
Lane 2: Control IgG IP in HEK-293T whole cell lysate.
Detection: Chemiluminescence with exposure time of 10 seconds.
Datasheets and documents
References
ab226197 has not yet been referenced specifically in any publications.
